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A B S T R A C T
Prosthetic valve endocarditis due to Cardiobacterium hominis is rare and recommended therapy includes a third
generation cephalosporin. We report a case of Cardiobacterium hominis endocarditis post transcatheter aortic
valve replacement in a patient with signiﬁcant beta-lactam antimicrobial sensitivities who was successfully
treated with ciproﬂoxacin monotherapy in conjunction with surgery.
Case report
A 78-year-old man was referred to the hospital by his primary care
physician for intravenous antibacterial therapy after 2 sets of blood
cultures grew Cardiobacterium hominis. One week earlier he had been
hospitalized for exertional chest tightness radiating into his jaw, bi-
lateral peripheral edema, and severe anemia due to lower gastro-
intestinal blood loss. Troponin was mildly elevated at 0.2 ng/mL, BNP
was 671 pg/mL and electrocardiogram showed sinus rhythm with
nonspeciﬁc repolarization changes. His hemoglobin was 6.7 g/dL and
he received 2 units of packed cells. During the transfusion he developed
a fever of 38.9 °C, so 2 sets of peripheral blood cultures were drawn. He
had no additional fevers, received no antimicrobials during that hos-
pital stay, and was discharged. Both blood culture sets grew
Cardiobacterium hominis, so the patient was asked to return to the
hospital.
On readmission he reported a history of intermittent low grade fe-
vers, chills, increasing fatigue, worsening anemia, and bilateral leg
swelling unresponsive to diuretics over the last 4 months. He had a
signiﬁcant cardiac history which included non-Q wave myocardial in-
farction in 2010, coronary angioplasty and stent of proximal left cir-
cumﬂex in 2013, cardiac catheterization with intervention to the left
anterior descending in 2013, repeat cardiac catheterization in 2015
with drug eluting stent to the left circumﬂex, and aortic stenosis with
transcatheter aortic valve replacement (TAVR) with a SAPIEN (Edwards
Lifesciences Corporation) valve in 2015. In addition he had a history of
chronic systolic and diastolic congestive heart failure, hypertension,
hyperlipidemia, and prostate cancer status post radiation treatments.
Vital signs on admission included a temperature of 36.9 °C, heart
rate of 94 beats per minute, respiratory rate of 18 breaths per minute,
blood pressure of 132/57mm Hg. Oxygen saturation was 99% on room
air. On physical exam a systolic murmur was noted with no peripheral
signs of endocarditis. The white blood cell count was 9.4×103/uL,
hemoglobin: 8.6 g/dL, and platelets were 210× 103/uL. The sedi-
mentation rate was 75mm/h, and C-reactive protein of 11.4 mg/dL.
The blood urea nitrogen (BUN) was elevated at 37mg/dL with a serum
creatinine of 1.25mg/dL. A transesophageal echocardiogram (TEE)
revealed a small vegetation or mass on the aortic valve with a mild to
moderate perivalvular leak and no abscess.
Repeat blood cultures drawn prior to the start of antimicrobials
grew Cardiobacterium hominis. Because the patient reported a history of
tongue swelling on cefazolin and a rash on penicillin, ciproﬂoxacin
400mg intravenously every 12 h was begun. The isolate was sent to a
reference laboratory for sensitivity testing. Minimum inhibitory con-
centration for the following antimicrobials was reported: ampicillin:
0.25 ug/mL (beta-lactamase negative), ceftriaxone: 1 ug/mL, cipro-
ﬂoxacin: ≤0.12 ug/mL, levoﬂoxacin: ≤0.06 ug/mL, meropenem:
0.12 ug/mL, trimethoprim-sulfamethoxazole: 0.5/9.5 ug/mL. Repeat
blood cultures were negative 4 days after the initiation of ciproﬂoxacin
therapy.
On day 6 of hospitalization, the patient experienced chest pressure
radiating into his jaw. This occurred 3 days after clopidogrel and aspirin
had been held for esophagogastroduodenoscopy and colonoscopy to
work up gastrointestinal bleeding. Troponin was 0.08 ng/mL and
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electrocardiogram showed a myocardial infarction with anterolateral
ST elevation. Emergent cardiac catheterization revealed severe left
main and right coronary artery stenosis of 99%. The patient underwent
emergent cardiac surgery consisting of removal of the SAPIEN valve,
coronary artery bypass graft× 3, and aortic valve replacement. The
surgeon stated that the SAPIEN valve was very diﬃcult to remove due
to many small vegetations on all of the leaﬂets, as well as below the
leaﬂets and between the native valve and the SAPIEN valve (Fig. 1).
On post-operative day 7 the patient developed a mediastinal and left
chest hematoma that led to cardiogenic shock and he was transferred to
the intensive care unit. He returned to the operating room for post-
operative bleeding where 2 liters of blood were removed from the right
chest. He remained in the intensive care unit for 8 days. On post-op-
erative day 15, the antibacterial was converted to oral ciproﬂoxacin
500mg twice daily. This was administered for an additional 4 weeks,
resulting in a total of a 6.5 weeks (6 weeks post- surgery) of treatment.
He received no other antimicrobials during hospitalization with the
exception of vancomycin for surgical prophylaxis. After a 2.5 week
hospital stay he was discharged to a rehabilitation center. Fourteen
months later, the patient is home, clinically stable with no signs of
recurrence. He did not experience any adverse events associated with
ciproﬂoxacin therapy. Levoﬂoxacin was recommended for dental pro-
phylaxis.
Discussion
Cardiobacterium hominis is a gram negative coccobacillus and a
member of the HACEK (Haemophilis species, Aggregatibacter species,
Cardiobacterium hominis, Eikenella corrodens and Kingella species) group
of bacteria known for their slow growing nature and insidious onset [1].
HACEK organisms are the causative pathogens in< 10% of cases of
community acquired infectious endocarditis, excluding infections in
intravenous drug users [2]. This percentage may increase with the
advent of matrix assisted laser desorption ionization-time of ﬂight mass
spectrometry (MALDI-TOF) technology that augments a laboratory’s
ability to detect this pathogen [3].
The American Heart Association/Infectious Disease Society of
America endocarditis guidelines recommend ceftriaxone or another
third or fourth-generation cephalosporin for treatment of HACEK en-
docarditis [2]. Patients with endocarditis who are unable to tolerate
ﬁrst line therapy can be treated with a ﬂuoroquinolone (ciproﬂoxacin,
levoﬂoxacin, or moxiﬂoxacin) for 6 weeks based on limited evidence
[2]. There are only six published case reports of Cardiobacterium hominis
that utilize ciproﬂoxacin as part of combination therapy or as salvage
therapy [4–9] (Table 1). Clinical cure was achieved in 5 of the 6 pa-
tients [4–8] with surgical intervention in 3 patients [7–9]. In 4 cases,
ciproﬂoxacin was combined with either rifampin, ceftriaxone, cef-
triaxone and gentamicin, or penicillin, gentamicin, and imipenem-ci-
lastatin [5,6,8,9]. Our case report is unique in that ciproﬂoxacin
monotherapy was used for the entire course of therapy, including step-
down to oral ciproﬂoxacin to complete 6 weeks of treatment avoiding
the long term use of a peripherally inserted central line.
Susceptibility testing for Cardiobacterium hominis is not readily
available at most institutions. In our case the organism was sent to a
reference laboratory and was found to be sensitive to all antimicrobials
tested including ciproﬂoxacin with an MIC of ≤0.12 ug/mL. This is
well below the Clinical and Laboratory Standards Institute (CLSI)
breakpoint of ≤1 ug/mL [10]. It is also in the range of MIC values
0.012–0.5 ug/mL reported in the literature [4,5,7]. In the case report by
Vogt et al., the authors performed a killing curve assay using the pa-
tient’s serum after receiving ciproﬂoxacin 200mg combined with
5×105 cfu/mL of organisms. With ciproﬂoxacin peak and trough
concentrations of 0.74 ug/mL and 0.14 ug/mL bacterial counts were
undetectable within 2 and 4 h respectively [4].
Cardiobacterium hominis has a strong association with aortic valve
infection and is known to produce large friable vegetations [1]. Surgical
intervention is required in 30–50% of patients [1,11]. Peripheral and
central nervous system emboli are reported in 51 and 21% of cases
respectively [11]. Our patient did not have any evidence of peripheral
or central nervous system emboli. Acute coronary syndrome is a rare
manifestation of endocarditis, but has been reported with other HACEK
organisms, including two cases with Cardiobacterium hominis [8,12]. In
a case series of patients with endocarditis that presented with acute
coronary syndrome, Courand et al. recommended consideration of
septic coronary embolism in patients with acute coronary syndrome,
elevation of inﬂammatory biomarkers, a normal coronary artery, and
unusual regurgitant valvulopathy [12]. Interestingly in our case the
patient presented with acute coronary syndrome that may have been
related to septic emboli, although he had an extensive cardiac history.
HACEK endocarditis is associated with a 93% cure rate and 4% rate
of hospital mortality [1,11]. Our patient responded well to a 6 week
course of ciproﬂoxacin therapy given ﬁrst intravenously and then by
mouth, in combination with surgical intervention. He also did not ex-
perience any adverse reactions that can be associated with long term
ﬂuoroquinolone therapy such as QTc prolongation, peripheral neuro-
pathy, or tendon rupture [13].
Conclusion
Monotherapy with intravenous ciproﬂoxacin followed by oral step
down therapy for 6 weeks combined with valve replacement was suc-
cessful in the treatment of prosthetic aortic valve endocarditis with
Fig. 1. Pathology reported a 3.0× 2.5× 0.5 cm aggregate of yellow to green, irregular friable tissue. Culture of the valve was negative after 10 days of incubation.
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possible septic coronary emboli in a patient allergic to penicillins and
cephalosporins.
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